Susan Knowles, MD
Rheumatology · Minden, NVNPI 1750583092
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,125 of the $14,221 with a category attached, or 71.2%. 24 manufacturers reported payments, led by Lilly USA, LLC at 53.9% of the total. Reporting peaked in 2019 at $6,420 and has fallen 94.3% since, to $367 in 2025.
Across 188 payments — averaging $75.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$8K
- Eli Lilly$2K
- AbbVie$1K
- Novartis$809
- Johnson & Johnson$640
- GSK$334
- plus $1K from 18 others
What the payments were for
- Consulting fees$10,12571%
- Food & beverage$3,91328%
- Education$1831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 8 | $7,671 |
| Eli Lilly | 1 | $2,475 |
| AbbVie | 50 | $1,124 |
| Novartis | 42 | $809 |
| Johnson & Johnson | 19 | $640 |
| GSK | 17 | $334 |
| Amgen | 17 | $287 |
| AstraZeneca(2 entities) | 3 | $175 |
| Pfizer | 3 | $101 |
| E.r. Squibb & Sons, L.L.C. | 4 | $98 |
| Aurinia Pharma U.S., Inc. | 5 | $97 |
| UCB, Inc. | 4 | $83 |
| 180 Medical, Inc. | 3 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $51 |
| Fresenius Kabi USA, LLC | 1 | $31 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Genentech, Inc. | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $17 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Medexus Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,221 in reported general payments places this provider in the 80th percentile of 43 rheumatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 94 | $702,969 |
| Humira(Cf) PenAdalimumab | 68 | $586,179 |
| RinvoqUpadacitinib | 57 | $365,020 |
| Cosentyx Unoready PenSecukinumab | 41 | $304,488 |
| Xeljanz XrTofacitinib Citrate | 35 | $270,039 |
| Orencia ClickjectAbatacept | 39 | $231,851 |
| OtezlaApremilast | 39 | $212,282 |
| TavneosAvacopan | 12 | $203,031 |
| Humira(Cf)Adalimumab | 24 | $163,244 |
| EnbrelEtanercept | 15 | $109,770 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $104,321 |
| XeljanzTofacitinib Citrate | 12 | $102,489 |
| SimponiGolimumab | 16 | $96,483 |
| Actemra ActpenTocilizumab | 18 | $67,495 |
| BenlystaBelimumab | 13 | $61,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Tavneos, Enbrel, Prolia | $287 | $553,70683 claims |
| AbbVieRinvoq, Humira(Cf) | $1,124 | $528,26381 claims |
| PfizerXeljanz | $101 | $102,48912 claims |
| Johnson & JohnsonSimponi | $640 | $96,48316 claims |
| GSKBenlysta | $334 | $61,94813 claims |
| Radius Health, Inc.Tymlos | $15 | $36,91214 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $21 | $3,95351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 rheumatology providers in Nevada.
Other rheumatology in Minden
- Ewa OlechLas Vegas$287K
- Walter ChathamLas Vegas$197K
- George KellyLas Vegas$185K
- Nasim DaoudLas Vegas$109K
- Christianne YungHenderson$101K
- Carolyn DenneheyReno$100K
- William KimLas Vegas$16K
- Aida LoudyiLas Vegas$10K
- Tudor JianuLas Vegas$8K
- Khalil Ibrahim BourjiLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.